Tecentriq & Avastin Non-Squamous Non-Small Cell Lung Cancer - Details


( Last Updated : July 20, 2020)
Generic Name:
Atezolizumab & Bevacizumab
Project Status:
Complete
Therapeutic Area:
NSQ-NSCLC
Manufacturer:
Hoffmann-La Roche Limited
Brand Name:
Tecentriq & Avastin
Project Line:
Reimbursement Review
Project Number:
PC0155-000
NOC Date:

Details


Strength:
1200 mg/20 mL (60 mg/mL) vial & 100 mg/4 mL (25 mg/mL) and 400mg/16mL (25 mg/mL) vials
Tumour Type:
Lung
Indications:
Non-Squamous Non-Small Cell Lung Cancer
Funding Request:
For the treatment of metastatic EGFR and/or ALK positive non-squamous non-small cell lung cancer in patients who have progressed on treatment with targeted therapies. Maintenance TECENTRIQ should be continued until loss of clinical benefit or unacceptable toxicity. Maintenance AVASTIN should be continued until disease progression or unacceptable toxicity.
Review Status:
Complete
Sponsor:
Hoffmann-La Roche Limited
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Do not reimburse
pERC Meeting:
Final Recommendation Issued:

Files

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.